ArticleClinical and translational science2026
Eltrombopag Combined With Cyclosporine A in the Treatment of Pediatric Patients With SAA: Establishing the Range for Eltrombopag Concentrations.
Article in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eltrombopag (ELT), as an oral thrombopoietin receptor agonist, in combination with cyclosporine A (CsA) provides a novel therapeutic option for pediatric severe aplastic anemia (SAA). However, current clinical protocols predominantly adopt fixed-dose regimens without adequate consideration of pediatric pharmacokinetic characteristics and drug-drug interactions, resulting in interindividual variability in efficacy and safety, as well as a lack of standardized therapeutic drug monitoring criteria for personalized treatment. This retrospective study analyzed treatment data from 83 pediatric patients with SAA (diagnosed at Kunming Children's Hospital between January 2020 and May 2025) to evaluate dose-concentration, concentration-efficacy, and concentration-adverse effects (ADRs) relationships, aiming to establish ELT concentration thresholds and reference ranges associated with therapeutic efficacy and ADRs. Results demonstrated a significant positive correlation between dosage and concentration (Pearson analysis). The study identified an efficacy threshold of 2.5 μg/mL (AUC = 0.85) and an ADRs threshold of 4.0 μg/mL (AUC = 0.82). Kaplan-Meier analysis revealed significant differences in time-to-response and time-to-adverse events among different concentration groups (4.0 μg/mL). The study confirms that ELT concentrations are closely associated with clinical efficacy and ADRs, and the established reference range of 2.5-4.0 μg/mL can serve as a basis for individualized pediatric treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.